This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

ASCVD and type 2 diabetes

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes. Hence, it is crucial to identify and treat people with type 2 diabetes and long-term atherosclerotic CVD risk early.
An early SHIFT in treatment could change lives

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.1
Patient Engagement Platform

Comorbid cardiovascular disease and diabetes can raise patient concerns and present particular management challenges. DiabetesWhatsNext.com can help answer patient questions, giving you more time to focus on their treatment.

Obesity and CVD

Explore a series of articles covering the link between obesity and cardiovascular disease (CVD), the global burden of CVD and the residual CVD risk rising from obesity.2

The ESC Congress 2024 brings together leading cardiologists and healthcare professionals from around the world to discuss the latest advancements and innovations in the field of cardiovascular medicine.

Hosted by the European Society of Cardiology (ESC), the international cardiovascular congress provides a platform for networking, sharing knowledge, and learning about new technologies and treatments. The event features a diverse range of sessions, including keynote lectures, symposia, and interactive workshops, covering topics such as prevention, diagnosis, and treatment of cardiovascular diseases.

Join Novo Nordisk from 30 August-2 September, 2024, at ESC 2024 in London - United Kingdom of Great Britain and Northern Ireland.

1.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

2.

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec.76(25)2982–3021. Doi: 10.1016/j.jacc.2020.11.010.

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are models and not real patients.

 

HQ24NNG00109, June 2024